TY - JOUR
T1 - Animal models in mycology
T2 - What have we learned over the past 30 years
AU - Kirkpatrick, William R.
AU - Wiederhold, Nathan P.
AU - Najvar, Laura K.
AU - Patterson, Thomas F.
N1 - Funding Information:
Disclosure W. R. Kirkpatrick: has served as an advisory board member for Astellas; N. P. Wiederhold: has served as an advisory board member for Viamet, Toyama Chemical Company, Astellas and Merck, provided consultancy for Toyama Chemical Company, received grants from Astellas, Pfizer, Merck, Schering-Plough, Basilea, and received travel funds from Viamet Pharmaceuticals; L. K. Najvar: has served as an advisory board member for Astellas; T. F. Patterson: has provided consultancy for Pfizer, Astellas, Merck, Toyoma Chemical Company, and Viamet, received grants form Astellas and Merck, and lectured for Merck and Pfizer.
PY - 2013/3
Y1 - 2013/3
N2 - Animal models have long been used to explore various pathophysiological, immunological and microbiological questions in the field of medical mycology. These models have been adapted and altered over time, yet their use has persisted. They remain valuable as research tools due to similarities to processes in human physiology and disease, and are evolving to include more fungal pathogens and infections that better mimic disease in humans. Animal availability, animal cost, housing requirements, the need for immunosuppression, the potential for tissue, fluid or blood samples, a researcher's familiarity with the model, as well as governmental or institutional regulations, must all be considered when selecting an appropriate one to use. Although the questions of interest have changed over the past 30 years, one idea persists: animal models are valuable tools in research that span the gap between the bench and the clinic.
AB - Animal models have long been used to explore various pathophysiological, immunological and microbiological questions in the field of medical mycology. These models have been adapted and altered over time, yet their use has persisted. They remain valuable as research tools due to similarities to processes in human physiology and disease, and are evolving to include more fungal pathogens and infections that better mimic disease in humans. Animal availability, animal cost, housing requirements, the need for immunosuppression, the potential for tissue, fluid or blood samples, a researcher's familiarity with the model, as well as governmental or institutional regulations, must all be considered when selecting an appropriate one to use. Although the questions of interest have changed over the past 30 years, one idea persists: animal models are valuable tools in research that span the gap between the bench and the clinic.
KW - Animal models
KW - Antifungal therapy
KW - Antifungal vaccines
KW - Fungal diagnostics
KW - Guinea pig
KW - Host response
KW - Mouse
KW - Pathogenesis
KW - Rabbit
KW - Rat
KW - Virulence
UR - http://www.scopus.com/inward/record.url?scp=84873721002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84873721002&partnerID=8YFLogxK
U2 - 10.1007/s12281-012-0126-6
DO - 10.1007/s12281-012-0126-6
M3 - Article
AN - SCOPUS:84873721002
SN - 1936-3761
VL - 7
SP - 68
EP - 78
JO - Current Fungal Infection Reports
JF - Current Fungal Infection Reports
IS - 1
ER -